TY - JOUR
T1 - Schizophrenia treatment preferences of psychiatrists versus guidelines
T2 - A European perspective
AU - Rojnic Kuzman, Martina
AU - Nordentoft, Merete
AU - Raballo, Andrea
AU - Mohr, Pavel
AU - Fiorillo, Andrea
AU - Dom, Geert
AU - Mihajlovic, Goran
AU - Jendricko, Tihana
AU - Chumakov, Egor
AU - Barjaktarov, Stojan
AU - Carpiniello, Bernardo
AU - Patarák, Michal
AU - Martin, Lorcan
AU - Dudek, Dominika
AU - Samochowiec, Jerzy
AU - Taube, Māris
AU - Courtet, Philippe
AU - Babic, Dragan
AU - Racetovic, Goran
AU - Catthoor, Kirsten
AU - Arango, Celso
AU - Maruta, Nataliya
AU - Basar, Koray
AU - Vahip, Simavi
AU - Szekeres, György
AU - Lien, Lars
AU - Popova, Ana
AU - Zhelev, Ruslan
AU - Jääskeläinen, Erika
AU - Delic, Mirjana
AU - Chkonia, Eka
AU - Chichai, Jana
AU - Telles-Correia, Diogo
AU - Cosman, Doina Constanta Maria
AU - Beezhold, Julian
AU - Falkai, Peter
N1 - Publisher Copyright:
© The Author(s), 2025.
PY - 2025/8/1
Y1 - 2025/8/1
N2 - Background We aimed to identify therapeutic approaches for managing schizophrenia in different phases and clinical situations - the prodromal phase, first-episode psychosis, cognitive and negative symptoms, pregnancy, treatment resistance, and antipsychotic-induced metabolic side effects - while assessing clinicians' adherence to guidelines. Methods A cross-sectional online survey was conducted in 2023 as part of the Ambassador project among psychiatrists and trainees from 35 European countries, based on a questionnaire that included six clinical vignettes (cases A-F). Additionally, a review of multiple guidelines/guidance papers was performed. Results The final analysis included 454 participants. Our findings revealed a moderate to high level of agreement among European psychiatrists regarding pharmacological treatment preferences for first-episode psychosis and cognitive and negative symptoms, prodromal symptoms and pregnancy, with moderate adherence to clinical guidelines. There was substantial similarity in treatment preferences for antipsychotic-induced metabolic side effects and treatment resistance; however, adherence to guidelines in these areas was only partial. Despite guideline recommendations, non-pharmacological treatments, including psychotherapy and recovery-oriented care, were generally underutilized, except for psychoeducation and lifestyle recommendations, and cognitive behavioural therapy for treatment of the prodromal phase. Contrary to guidelines, cognitive remediation and physical exercise for cognitive symptoms were significantly neglected. Conclusions These discrepancies highlight the need for effective implementation strategies to bridge the gap between research evidence, clinical guidelines/guidance papers, and real-world clinical practice. Clinicians' unique combination of knowledge and experience positions them to shape future guidelines, especially where real-world practice diverges from recommendations, reinforcing the need to integrate both research evidence and clinical consensus.
AB - Background We aimed to identify therapeutic approaches for managing schizophrenia in different phases and clinical situations - the prodromal phase, first-episode psychosis, cognitive and negative symptoms, pregnancy, treatment resistance, and antipsychotic-induced metabolic side effects - while assessing clinicians' adherence to guidelines. Methods A cross-sectional online survey was conducted in 2023 as part of the Ambassador project among psychiatrists and trainees from 35 European countries, based on a questionnaire that included six clinical vignettes (cases A-F). Additionally, a review of multiple guidelines/guidance papers was performed. Results The final analysis included 454 participants. Our findings revealed a moderate to high level of agreement among European psychiatrists regarding pharmacological treatment preferences for first-episode psychosis and cognitive and negative symptoms, prodromal symptoms and pregnancy, with moderate adherence to clinical guidelines. There was substantial similarity in treatment preferences for antipsychotic-induced metabolic side effects and treatment resistance; however, adherence to guidelines in these areas was only partial. Despite guideline recommendations, non-pharmacological treatments, including psychotherapy and recovery-oriented care, were generally underutilized, except for psychoeducation and lifestyle recommendations, and cognitive behavioural therapy for treatment of the prodromal phase. Contrary to guidelines, cognitive remediation and physical exercise for cognitive symptoms were significantly neglected. Conclusions These discrepancies highlight the need for effective implementation strategies to bridge the gap between research evidence, clinical guidelines/guidance papers, and real-world clinical practice. Clinicians' unique combination of knowledge and experience positions them to shape future guidelines, especially where real-world practice diverges from recommendations, reinforcing the need to integrate both research evidence and clinical consensus.
KW - Europe
KW - guidelines
KW - psychopharmacology
KW - psychotherapy
KW - schizophrenia
UR - https://www.scopus.com/pages/publications/105013212063
U2 - 10.1192/j.eurpsy.2025.10072
DO - 10.1192/j.eurpsy.2025.10072
M3 - Article
C2 - 40745910
AN - SCOPUS:105013212063
SN - 0924-9338
VL - 68
JO - European Psychiatry
JF - European Psychiatry
IS - 1
M1 - e107
ER -